keyword
https://read.qxmd.com/read/38130516/effectiveness-of-rituximab-and-its-biosimilar-in-treating-adult-steroid-dependent-minimal-change-disease-and-relapse
#21
Hui Yi Shan
Minimal change disease (MCD) is an important cause of nephrotic syndrome in adults. Its course is often complicated by frequent relapses and steroid dependence. Most of the treatment experience of MCD comes from management of pediatric patients rather than adult patients. In this report, the author describes successful experience of using rituximab (RTX) and its biosimilar, RTX-pvvr (ruxience), to treat steroid-dependent MCD and relapses in adult patients. This is the first report of using a RTX biosimilar to treat MCD...
November 2023: Curēus
https://read.qxmd.com/read/38113869/rituximab-use-in-paediatric-nephrology-practice-in-t%C3%A3-rkiye-trtx
#22
JOURNAL ARTICLE
Ahmet Ünal, Emre Leventoğlu, Sevcan A Bakkaloğlu
AIM: Rituximab (RTX) is a genetically engineered chimeric monoclonal antibody which binds directly to CD20 antigen and mediates inhibition of B cell development. Although RTX has been widely used in paediatric nephrology, there is no routine protocol for its use. In this study, paediatric nephrologists in Türkiye were asked to fill out a questionnaire to understand their practice in using RTX. This study aimed to determine common practices and clarify the uncertainties regarding the use of RTX in paediatric nephrology...
December 19, 2023: Nephrology
https://read.qxmd.com/read/38056198/effect-of-rituximab-in-patients-with-pla2r-associated-membranous-nephropathy-and-malignancy
#23
JOURNAL ARTICLE
Yanhong Guo, Mingjing Ren, Yulin Wang, Zihan Zhai, Lu Yu, Liuwei Wang, Lin Tang
INTRODUCTION: Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is a common cause of nephrotic syndrome in nondiabetic adults who are also within the common age group for malignancy. How to treat patients with PLA2R-associated MN and malignancy effectively and safely still requires careful consideration. The aim of our study was to examine the outcomes and safety of rituximab (RTX) in these patients. METHODS: Retrospective analysis of clinical data was performed on 15 patients with PLA2R-associated MN and malignancy...
December 5, 2023: International Immunopharmacology
https://read.qxmd.com/read/38010466/rituximab-in-combination-with-cyclosporine-and-steroid-pulse-therapy-for-childhood-onset-multidrug-resistant-nephrotic-syndrome-a-multicenter-single-arm-clinical-trial-jskdc11-trial
#24
JOURNAL ARTICLE
Kandai Nozu, Mayumi Sako, Seiji Tanaka, Yuji Kano, Yoko Ohwada, Tamaki Morohashi, Riku Hamada, Yasufumi Ohtsuka, Masafumi Oka, Koichi Kamei, Aya Inaba, Shuichi Ito, Tomoyuki Sakai, Hiroshi Kaito, Yuko Shima, Kenji Ishikura, Hidefumi Nakamura, Koichi Nakanishi, Tomoko Horinouchi, Akihide Konishi, Takashi Omori, Kazumoto Iijima
BACKGROUND: Only 80% of children with idiopathic nephrotic syndrome respond well to glucocorticoid therapy. Multidrug-resistant nephrotic syndrome (MRNS) is associated with a poor kidney prognosis. Several retrospective studies have identified rituximab as an effective treatment for MRNS; however, prospective studies are required to assess its efficacy and safety. METHODS: We conducted a multicenter, non-blinded, single-arm trial to investigate the efficacy and safety of rituximab in patients with childhood-onset MRNS who were resistant to cyclosporine and more than three courses of steroid pulse therapy...
November 27, 2023: Clinical and Experimental Nephrology
https://read.qxmd.com/read/38007057/proteinuria-selectivity-index-in-renal-disease
#25
REVIEW
Wen Liu, Zhi-Hang Su, Qi-Jun Wan
One of the main barriers to early detection and subsequent prevention of kidney diseases is the accessibility and feasibility of testing, especially in urine research. The proteinuria selectivity index (PSI or SI) is a method used to assess changes in glomerular permeability in glomerular diseases. It describes the pattern of proteinuria by comparing the clearance rates of large molecular proteins and transferrin, categorizing it as selective or non-selective. PSI is widely applied for kidney disease classification, prediction of corticosteroid efficacy, and prognosis...
November 23, 2023: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://read.qxmd.com/read/38004046/how-to-choose-the-right-treatment-for-membranous-nephropathy
#26
REVIEW
Luigi Peritore, Vincenzo Labbozzetta, Veronica Maressa, Chiara Casuscelli, Giovanni Conti, Guido Gembillo, Domenico Santoro
Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, ACE inhibitors or angiotensin-receptor blockers, lipid-lowering agents and anticoagulants...
November 14, 2023: Medicina
https://read.qxmd.com/read/37996443/the-extrafollicular-b-cell-response-is-a-hallmark-of-childhood-idiopathic-nephrotic-syndrome
#27
JOURNAL ARTICLE
Tho-Alfakar Al-Aubodah, Lamine Aoudjit, Giuseppe Pascale, Maneka A Perinpanayagam, David Langlais, Martin Bitzan, Susan M Samuel, Ciriaco A Piccirillo, Tomoko Takano
The efficacy of the B cell-targeting drug rituximab (RTX) in childhood idiopathic nephrotic syndrome (INS) suggests that B cells may be implicated in disease pathogenesis. However, B cell characterization in children with INS remains limited. Here, using single-cell RNA sequencing, we demonstrate that a B cell transcriptional program poised for effector functions represents the major immune perturbation in blood samples from children with active INS. This transcriptional profile was associated with an extrafollicular B cell response marked by the expansion of atypical B cells (atBCs), marginal zone-like B cells, and antibody-secreting cells (ASCs)...
November 24, 2023: Nature Communications
https://read.qxmd.com/read/37963441/efficacy-of-rituximab-for-minimal-change-disease-and-focal-segmental-glomerulosclerosis-with-frequently-relapsing-or-steroid-dependent-nephrotic-syndrome-in-adults-a-chinese-multicenter-retrospective-study
#28
MULTICENTER STUDY
Lan Lan, Yuxin Lin, Binfeng Yu, Yin Wang, Hong Pan, Huijing Wang, Xiaowei Lou, Xiabing Lang, Qiankun Zhang, Lie Jin, Yi Yang, Liang Xiao, Jianghua Chen, Fei Han
INTRODUCTION: Rituximab has been proven effective and safe in pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome (FR/SDNS). We aimed to analyze the efficacy and safety of rituximab in adult FR/SDNS patients with minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). METHODS: A retrospective cohort study at three nephrology centers in China included adult FR/SDNS patients with biopsy-proven MCD or FSGS. Primary outcomes were relapse frequency and first relapse-free survival time...
2024: American Journal of Nephrology
https://read.qxmd.com/read/37924431/practice-patterns-of-rituximab-for-primary-membranous-nephropathy-2021-in-japan-a-web-based-survey-of-board-certified-nephrologists
#29
JOURNAL ARTICLE
Yoshitaka Miyaoka, Noriaki Kurita, Tadashi Sofue, Hiroki Nishiwaki, Masahiro Koizumi, Sayaka Shimizu, Sho Sasaki, Takuji Ishimoto, Takehiko Wada
BACKGROUND: Although rituximab (RTX) is recommended by kidney disease improving global outcomes as one of the standard therapies for primary membranous nephropathy (pMN), given the constraint of insurance coverage, it is not clear how the drug is used in Japan. METHODS: This cross-sectional study was conducted via a web-based survey between November and December 2021. The participants were certified nephrologists and recruited through convenience sampling. Experience with RTX for pMN was compared to experience with RTX for minimal change nephrotic syndrome (MCNS)...
November 4, 2023: Clinical and Experimental Nephrology
https://read.qxmd.com/read/37901702/review-of-the-role-of-rituximab-in-the-management-of-adult-minimal-change-disease-and-immune-mediated-focal-and-segmental-glomerulosclerosis
#30
REVIEW
Ahsan Aslam, Abbal Koirala
BACKGROUND: Minimal change disease and primary FSGS are podocytopathies but are also immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance between autoreactive B and T cells in favor of regulatory B and T cells. The consequences are decreased production of cytokines, chemokines, and permeability factors by these cells. In the past decade, we have seen the discovery of autoantibodies mediating nephrotic syndrome (anti-annexin A2 antibody, anti-UCHL1 antibody, and anti-nephrin antibody), and rituximab decreases their production...
2023: Glomerular diseases
https://read.qxmd.com/read/37899889/dnajb9-fibrillary-glomerulonephritis-with-membranous-like-pattern-a-case-based-literature-review
#31
Nikolaos Sabanis, Paraskevi Liaveri, Virginia Geladari, George Liapis, George Moustakas
Fibrillary glomerulonephritis (FGN) is a rare immune-mediated glomerular disease traditionally characterized by the presence of amyloid-like, randomly aligned, fibrillary deposits in the capillary wall, measuring approximately 20 nm in diameter and composed of polyclonal IgG. FGN is usually a primary disease with no pathognomonic clinical or laboratory findings. More than that, on light microscopic evaluation, it can receive various histological patterns, rendering its diagnosis indistinguishable. However, the identification by immunohistochemistry of a novel biomarker, DNA-J heat-shock protein family member B9 (DNAJB9), has created a new era in FGN diagnosis even in the absence of electron microscopy...
October 2023: Curēus
https://read.qxmd.com/read/37885853/retracted-rituximab-may-have-positive-effect-on-refractory-nephrotic-syndrome-a-meta-analysis-of-randomized-trials
#32
Computational And Mathematical Methods In Medicine
[This retracts the article DOI: 10.1155/2022/3008597.].
2023: Computational and Mathematical Methods in Medicine
https://read.qxmd.com/read/37818552/the-importance-of-sphingomyelin-phosphodiesterase-acid-like-3b-smpdl-3b-levels-in-kidney-biopsy-specimens-of-children-with-nephrotic-syndrome
#33
JOURNAL ARTICLE
Muhammet Kaya, İlknur Girişgen, Nagihan Yalçın, Tülay Becerir, Hande Şenol, Gülsün Gülten, Selcuk Yüksel
OBJECTIVE: It remains unclear whether the low amount of SMPDL-3b required for rituximab binding is the cause of treatment resistance in patients with treatment-resistant nephrotic syndrome with advanced podocyte injury. Given the limited number of studies on the relationship between rituximab and SMPDL-3b, this study was conducted to assess whether SMPDL-3b levels in pretreatment renal biopsy specimens can be used to predict the clinical effectiveness of immunosuppressive drugs, especially rituximab, in children with nephrotic syndrome...
October 11, 2023: Fetal and Pediatric Pathology
https://read.qxmd.com/read/37815750/a-case-of-protocadherin-fat1-positive-membranous-nephropathy-secondary-to-hematopoietic-stem-cell-transplantation
#34
JOURNAL ARTICLE
Nicola Mongera, Werner Passler, Sanjeev Sethi, Nicolas Kozakowski, Maria Grazia Tabbì
No abstract text is available yet for this article.
October 10, 2023: Journal of Nephrology
https://read.qxmd.com/read/37815432/rituximab-in-idiopathic-nephrotic-syndrome-still-waiting-for-stronger-evidences
#35
JOURNAL ARTICLE
Vera Maria Santoro Belangero
No abstract text is available yet for this article.
October 6, 2023: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://read.qxmd.com/read/37795285/a-systematic-review-and-meta-analysis-of-rituximab-associated-infections-among-children-and-adolescents-with-glomerular-disease-focus-on-the-risk-of-infections
#36
JOURNAL ARTICLE
Zhara Pouransiri, Farahnak Assadi, Masoumeh Mohkam, Nakysa Hooman, Zahra Rostami, Mojgan Mazaheri, Anoush Azarfar, Fatemeh Ghane Sharbaf
OBJECTIVE: This systematic review and meta-analysis aimed to explore rituximab (RTX) associated infectious complications in children with glomerular disease. METHODS: We performed an electronic search of PubMed, International Scientific Information (ISI), Scopus, and EMBASE between January 2010 and July 2021. Infection rates and total drug-related adverse events were the outcomes. Statistical heterogeneity was evaluated by using the I2 statistic. When there was statistical evidence of heterogeneity ( I 2 > 50%, p > 0...
2023: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://read.qxmd.com/read/37777061/ofatumumab-in-rituximab-resistant-and-rituximab-intolerant-patients-with-primary-membranous-nephropathy
#37
JOURNAL ARTICLE
Manuel Alfredo Podestà, Matias Trillini, Valentina Portalupi, Alessia Gennarini, Federica Tomatis, Alessandro Villa, Annalisa Perna, Nadia Rubis, Giuseppe Remuzzi, Piero Ruggenenti
RATIONALE & OBJECTIVE: Rituximab is the first-choice therapy for patients with primary membranous nephropathy (MN) and nephrotic syndrome (NS). However, approximately 30% of patients are treatment-resistant or become treatment-intolerant with hypersensitivity reactions upon repeated drug exposures. We aimed to assess whether ofatumumab, a fully human second-generation anti-CD20 antibody, could be a valuable alternative to rituximab in this population. STUDY DESIGN: Case series...
September 28, 2023: American Journal of Kidney Diseases
https://read.qxmd.com/read/37728654/-general-recommendations-for-the-management-of-glomerular-diseases-2023
#38
JOURNAL ARTICLE
Martin Windpessl, Philipp Gauckler, Emanuel Zitt, Karl Lhotta, Cihan Ay, Kathrin Eller, Balazs Odler, Irmgard Neumann, Michael Rudnicki, Andreas Kronbichler, Marcus D Säemann
Glomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreover, practical recommendations for the prevention of thromboembolism in states of nephrosis and for the prophylaxis of Pneumcystic jirovecii pneumonia are provided...
August 2023: Wiener Klinische Wochenschrift
https://read.qxmd.com/read/37728650/-diagnosis-and-therapy-of-membranous-nephropathy-2023
#39
JOURNAL ARTICLE
Marcus D Säemann, Balazs Odler, Martin Windpessl, Heinz Regele, Kathrin Eller, Irmgard Neumann, Michael Rudnicki, Philipp Gauckler, Andreas Kronbichler, Maarten Knechtelsdorfer
Membranous nephropathy (MN) is an immune-complex glomerulonephritis and is one of the most common causes of nephrotic syndrome in adults and is also one of the autoimmune kidney diseases with the highest rate of spontaneous remission. The most common autoantigen (> 70% of cases) is directed against the phospholipase A2 receptor (PLA2-R) and, with its detection and clinical course, allows for excellent diagnostics as well as optimal therapy monitoring. Other autoantigens are constantly being published and will enable an autoantigen-based diagnostic and therapeutic algorithm for MN in the future...
August 2023: Wiener Klinische Wochenschrift
https://read.qxmd.com/read/37728648/-diagnosis-and-treatment-of-minimal-change-disease-in-adults-2023
#40
JOURNAL ARTICLE
Philipp Gauckler, Heinz Regele, Kathrin Eller, Marcus D Säemann, Karl Lhotta, Emanuel Zitt, Irmgard Neumann, Michael Rudnicki, Balazs Odler, Andreas Kronbichler, Martin Windpessl
Minimal change disease is a glomerulopathy that clinically manifests as acute onset nephrotic syndrome. A diagnosis is made by renal biopsy, implying the absence of glomerular lesions on light microscopy but detection of extensive podocyte foot process effacement on electron miscroscopy. Considering the typically excellent response to immunosuppressive measures (especially to glucocorticoids), an autoimmune pathogenesis is assumed. Although general prognosis is overall beneficial, steroid-dependent, steroid-resistant and frequently-relapsing disease courses may complicate the management of these patients and necessitate the use of alternative immunosuppressive treatment strategies...
August 2023: Wiener Klinische Wochenschrift
keyword
keyword
81316
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.